November 2022 - CBDWire

TuesdayNov 29, 2022 1:30 pm

Prime Harvest Inc. Positioned to Lead California’s Cannabis Market with Direct-to-Consumer Expansion

Prime Harvest is the parent company of Jaxx Cannabis, its D2C operations actively expanding throughout California Prime Harvest’s brand partners strongly positioned across multiple segments of the cannabis value chain Brand partners include Mary's Medicinals, STIIIZY, Lime Cannabis, and Tonik Revenue diversification is critical to sustainable growth in the cannabis industry, and it’s central to the strategy of Prime Harvest, a technology-focused, full-service cannabis corporation. With a strong portfolio of successful brand partners, Prime Harvest is strongly positioned to lead California’s sector through robust diversification across multiple segments of the cannabis value chain. “Our approach is to create strong alliances…

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

WednesdayNov 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

ThursdayNov 17, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine

Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched…

FridayNov 11, 2022 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo According to a Zacks SCR report, the findings support their $15 share valuation of the company Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one…

WednesdayNov 09, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Defines Path to Profitability and Portfolio Expansion with Proposed Franchise Global Health Inc. Acquisition

Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreement The deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and a growing wholesale market FGH’s acquisition adds to Flora’s expanding list of subsidiaries which currently comprise Vessel Brand Inc. and JustCBD, among others, and it is expected to deliver at least $3 million in…

TuesdayNov 08, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under control With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint FGH is focused on the German market, where its subsidiary was the first company to sell cannabis Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of…

FridayNov 04, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause Lexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026 In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control.…

News and publishing service for CBD related companies

Contact us: 303.498.7722

Month: November 2022